Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Company Announcement Net sales of DARZALEX in the third quarter of 2017 totaled USD 317 million Genmab will receive royalties on worldwide net sales from Janssen Biotech,...
-
Selskabsvedtægter for Genmab A/S dateret den 5. oktober 2017 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
-
Genmab A/S has published its Articles of Association dated October 5, 2017. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel Curtis...
-
Company Announcement Phase II study of tisotumab vedotin in patients with advanced cervical cancer Study provides opportunity for accelerated approval and is expected to begin in the...
-
Company Announcement Copenhagen, Denmark; October 5, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,019 restricted stock units and...
-
Selskabsvedtægter for Genmab A/S dateret den 26. september 2017 er blevet offentliggjort. Selskabsvedtægterne er tilgængelige på Genmabs hjemmeside:...
-
Genmab A/S has published its Articles of Association dated September 26, 2017. The Articles of Association can be found on Genmab’s website: http://ir.genmab.com/releases.cfm Contact: Rachel...
-
Company Announcement DARZALEX approved for relapsed or refractory multiple myeloma in Japan Genmab to receive USD 25 million in milestone payments upon first commercial sale in...
-
Company Announcement Copenhagen, Denmark; September 26, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 23,670 shares as a consequence of the exercise of employee...
-
Media Release Copenhagen, Denmark; September 5, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will give a company update at the Morgan Stanley...